ArticleCell reports. Medicine2023

METTL3 drives NAFLD-related hepatocellular carcinoma and is a therapeutic target for boosting immunotherapy.

Yasi Pan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.